Augmentin XR vs Regular Augmentin Tablets

Augmentin XR vs Regular Augmentin: Main Product Differences

The defining difference between Augmentin XR and conventional Augmentin tablets is the release formulation. XR is an extended-release combination product designed to provide a more sustained profile of amoxicillin concentrations. Regular Augmentin tablets release their active ingredients through an immediate-release formulation. They belong to the same broad amoxicillin/clavulanate family but are not identical pharmaceutical products.

Both formulations contain the antibacterial amoxicillin and the beta-lactamase inhibitor clavulanate potassium. Neither is plain amoxicillin, and neither should be identified using the amoxicillin quantity alone. The clavulanic-acid amount and release characteristics are important parts of the approved product identity.

XR contains 1,000 mg of amoxicillin and 62.5 mg of clavulanic acid per tablet. Regular Augmentin tablets contain 250 mg/125 mg, 500 mg/125 mg or 875 mg/125 mg. This difference changes the amoxicillin-to-clavulanate ratio as well as the formulation profile.

FDA labeling expressly distinguishes their indications, administration requirements and substitution rules. A prescription for regular Augmentin is not an automatic authorization to dispense XR, and an XR prescription does not authorize replacing it with conventional tablets because of price or availability.

The comparison also includes two separate commercial questions: whether a particular product has an FDA approval or marketing record, and whether a specific pharmacy can currently dispense it. Those questions require different evidence.

The principal product differences are summarized in the table below.

Extended-Release Bilayer Design vs Immediate-Release Tablets

Augmentin XR is described in FDA labeling as a film-coated, bilayer, scored extended-release tablet. The tablet contains amoxicillin in a formulation designed to extend its plasma concentration profile compared with immediate-release tablets. Its release technology is an important part of the product's regulatory and pharmaceutical identity.

Conventional Augmentin tablets do not reproduce the XR release design. Although they contain the same two active components, the time course of amoxicillin exposure differs. This prevents a comparison based only on the number of milligrams printed on a package.

The FDA states that XR provides extended amoxicillin exposure compared with ordinary immediate-release Augmentin tablets. It specifically notes that two regular Augmentin 500 mg/125 mg tablets are not equivalent to one XR 1,000 mg/62.5 mg tablet. The statement reflects both the release characteristics and the component-strength differences.

Extended release should not be interpreted as a general claim that XR treats every infection better or is appropriate for every patient. FDA approval is tied to specific indications and labeled conditions. The clinical relevance of the exposure profile depends on the organism and treatment context.

The XR bilayer structure also has product-specific handling instructions. Its tablet configuration should not be treated as interchangeable with a conventional tablet merely because both are scored or film-coated.

This section explains the release-mechanism distinction. Individual XR product identification, labeling and brand-specific details remain on the Augmentin XR guide.

XR 1,000/62.5 mg vs Regular 500/125 and 875/125 mg

Augmentin XR uses the complete strength pair 1,000 mg/62.5 mg per extended-release tablet. Regular tablets use different pairs, including 500 mg/125 mg and 875 mg/125 mg. The quantities must be read together because each active component contributes to the product's identity.

The XR strength has a 16:1 amoxicillin-to-clavulanic-acid ratio. The conventional 500 mg/125 mg tablet has a 4:1 ratio, while the 875 mg/125 mg tablet has a 7:1 ratio. The standard 250 mg/125 mg tablet has a 2:1 ratio. These differences show why an amoxicillin-only comparison is incomplete.

Matching an amoxicillin total by combining conventional tablets would not reproduce the same clavulanate amount and would not reproduce XR's extended-release profile. The FDA explicitly identifies this as a non-substitution boundary.

The numbers in this section are product-label facts rather than instructions for converting a prescription. They should not be used to calculate substitute tablet combinations, different treatment schedules or patient-specific doses.

Prescription instructions must identify the intended formulation, and the pharmacist must verify the product dispensed. If the prescribed item is unavailable, any alternative requires appropriate professional review.

The Augmentin 500/125 mg guide and 875/125 mg guide provide further conventional-strength details.

FDA-Labeled Uses: XR vs Conventional Augmentin Tablets

The July 2026 FDA combined Augmentin labeling assigns different indication categories to XR and conventional tablets. Augmentin XR is indicated for community-acquired pneumonia and acute bacterial sinusitis under specified conditions. The labeling identifies adults and pediatric patients weighing 40 kg or more who can swallow tablets as its applicable patient group.

Conventional Augmentin tablets have a broader set of labeled infection categories, including certain lower respiratory tract, sinus, ear, skin and urinary tract infections caused by designated susceptible microorganisms. The categories overlap in some areas, but they should not be interpreted as identical approvals for identical clinical circumstances.

Augmentin XR also has an organism-specific limitation involving Streptococcus pneumoniae. The FDA states that XR is not indicated for community-acquired pneumonia or acute bacterial sinusitis caused by S. pneumoniae with penicillin minimum inhibitory concentrations of 4 mcg/mL or greater. This limitation cannot be generalized to every infection or used for patient self-diagnosis.

These differences are important because a product with an extended-release design is not inherently a broader-purpose antibiotic. Its labeled indication remains product-specific, even though it contains the same two active ingredients found in regular Augmentin.

A prescription is based on clinical assessment, including relevant patient circumstances and bacterial susceptibility considerations. A price, inventory listing or preference for a particular tablet formulation should not determine the antibiotic selected.

This page does not compare treatment success rates or claim that XR is more effective than conventional Augmentin. It explains the regulatory distinction between their FDA-labeled uses.

Why Food and Tablet-Handling Instructions Differ

FDA labeling distinguishes the administration characteristics of Augmentin XR from those of conventional Augmentin tablets. The XR release formulation is associated with product-specific absorption considerations, while ordinary immediate-release tablets have their own labeled food guidance.

The July 2026 XR labeling specifies administration at the start of a meal and cautions against use with a high-fat meal because the absorption profile of the components can be affected. This is a product-label distinction, not a recommendation to modify an existing prescription or meal routine independently.

Conventional Augmentin tablets may be taken without regard to meals according to the label, although taking them at the start of a meal is described as helping minimize gastrointestinal intolerance and enhance clavulanate absorption.

XR tablets are scored, but the presence of a score line does not mean the release formulation can be crushed or converted into an immediate-release product. FDA labeling permits a specific handling approach involving division along the score line for patients who have difficulty swallowing the tablet whole, with both halves taken immediately. That limited labeled provision is not permission to create a new strength or dose.

A scored conventional tablet may have different handling considerations from an XR tablet. The actual manufacturer's labeling and pharmacist's instructions should be consulted rather than assuming all Augmentin tablet score lines serve the same purpose.

These distinctions matter for pharmacy counseling and product verification. They do not support patient-directed substitution, splitting for cost savings or independent changes to prescribed administration.

Augmentin XR FDA History, December 2025 Approval and Market-Status Evidence

Augmentin XR has a separate U.S. regulatory history. Its original FDA approval is associated with NDA 050785 and an initial approval date in September 2002. This historical approval establishes that XR is a distinct extended-release product rather than a newly invented strength of conventional Augmentin.

On December 9, 2025, the FDA announced an Augmentin XR approval granted to USAntibiotics through the Commissioner's National Priority Voucher pilot program. The agency explained that the review concerned domestic antibiotic manufacturing capacity and supply-chain resilience. That announcement is a verified regulatory event, but it should not be presented as proof that all U.S. pharmacies began carrying the original branded product.

The FDA's authorized-generics listing also identifies an authorized generic of Augmentin XR at 1,000 mg/62.5 mg and records December 15, 2025 as its market-entry date. This is evidence of reported authorized-generic market entry, distinct from an ordinary ANDA approval. It does not supply real-time geographic inventory or an individual pharmacy's dispensing capability.

The FDA Orange Book includes historical extended-release amoxicillin/clavulanate records, including an ANDA associated with Sandoz. Regulatory approval entries, authorized-generic market records and currently marketed package listings describe different facts and must not be combined into a single unsupported availability claim.

The July 2026 Augmentin labeling also identifies branded XR package configurations and NDCs. A published package listing supports product identification, but does not establish whether a particular bottle is commercially obtainable today.

This comparison therefore separates regulatory status, market-entry evidence and current fulfillment. The full XR brand history and product record belong in the Augmentin XR guide, while this section explains why those records matter when comparing XR with ordinary tablets.

Augmentin XR Packaging: 28-Tablet and 40-Tablet FDA Records

The July 2026 FDA combined Augmentin labeling identifies two branded XR package configurations: a bottle of 28 extended-release tablets and a bottle of 40 extended-release tablets. Both contain the 1,000 mg/62.5 mg bilayer XR formulation.

The listed 28-tablet package uses NDC 81964-020-28, while the listed 40-tablet package uses NDC 81964-020-40. The labeling also describes these packages in relation to specified XR treatment-course packaging. Those package descriptions should not be converted into prescribing advice.

A package NDC can help a pharmacy identify the listed brand presentation, but it does not prove that the product is in stock. The existence of two labeled quantities also does not mean that every pharmacy offers both or that a particular prescription must be filled using one complete original bottle.

Regular Augmentin tablets have different NDC families and package configurations. Their package identifiers should not be used to confirm an XR order, even if the same brand name appears in a distributor's catalog.

The prescribed quantity and actual dispensed product must be verified independently of manufacturer stock-bottle configuration. Changing a tablet count or substituting a conventional tablet because a package size differs is not an appropriate self-directed response.

The table below records the XR product identifiers from FDA labeling without representing them as current retail inventory.

XR Generic Status and Why Regular Tablets Cannot Replace XR

Pharmacy substitution depends on the actual approved product, therapeutic-equivalence information and applicable prescription requirements. A generic conventional Augmentin tablet belongs to the immediate-release category and cannot be treated as an XR equivalent simply because both contain amoxicillin and clavulanate.

An appropriate generic XR comparison requires the extended-release dosage form, corresponding 1,000 mg/62.5 mg strength and applicable FDA equivalence relationship. A historical ANDA record and a separately documented authorized generic are not identical regulatory pathways, even when both involve the XR product family.

An authorized generic is generally marketed under the original brand's NDA without the brand name on its label. A conventional ANDA generic is approved through a separate abbreviated application. These distinctions can matter when interpreting FDA records or a pharmacy catalog.

The FDA specifically prohibits milligram-for-milligram substitution between XR and immediate-release formulations. Neither a pharmacist nor a patient should assume that combining conventional tablets can recreate the XR release profile or ingredient ratio.

When the intended XR product cannot be located, the pharmacy should clarify actual supply and discuss appropriate next steps with the prescriber. A lower-priced conventional tablet or a differently labeled generic is not automatically an acceptable replacement.

The Augmentin vs generic guide explains the general ANDA and therapeutic-equivalence framework. This section concentrates on the unique extended-release boundary.

How XR and Regular Augmentin Differ in Pharmacy Pricing and Insurance

Augmentin XR and conventional Augmentin tablets are different commercial products. Their strengths, release types, approved product records and package configurations differ, so an ordinary 875 mg/125 mg tablet quote is not a valid substitute for a 1,000 mg/62.5 mg XR quotation.

Even where both products are approved, their actual retail costs can depend on manufacturer or labeler, supply arrangements, pharmacy location, prescribed quantity and payment method. Published reference prices may be outdated or may describe a generic rather than the original brand.

An authorized generic XR listing may have a different commercial identity from original branded XR, but its existence does not establish that either is available at a particular pharmacy. Price estimates should be classified using the product actually offered, not the broad Augmentin name alone.

Insurance formularies can distinguish conventional immediate-release tablets, XR and authorized generic products. Coverage of generic amoxicillin/clavulanate tablets does not guarantee coverage of XR, and a plan's listed XR status does not guarantee product supply.

Patients and pharmacists should preserve the prescribed medicine's release type and complete strength when requesting a quotation. A price comparison should not become a suggestion to switch regimens or combine ordinary tablets.

The Augmentin price guide addresses broader branded costs, generic combination pricing addresses generic quotations and insurance coverage covers commercial formulary checks. This page limits the discussion to why XR and regular tablet prices are not interchangeable.

Augmentin XR vs Regular Tablets: Prescription Verification Checklist

A prescription comparison begins with the exact dosage form: Augmentin XR extended-release tablet or conventional immediate-release Augmentin tablet. The full pair of active-component strengths should be checked before a pharmacy quote or product record is accepted.

The pharmacist should verify the prescribed product and any proposed generic against applicable approval and substitution requirements. The FDA's product-specific XR restrictions must be respected regardless of differences in stock, price or package quantity.

Safety is another reason not to treat the products as automatically equivalent. Both contain amoxicillin and clavulanate and share important warnings about serious beta-lactam hypersensitivity, liver-related adverse reactions and antibiotic-associated diarrhea. XR has additional formulation-specific precautions, including its labeled food and administration instructions.

Renal impairment is another product-specific distinction. Under the July 2026 FDA labeling, patients with severe renal impairment (GFR below 30 mL/min) or receiving intermittent hemodialysis should not receive Augmentin XR Extended-Release Tablets. Certain conventional Augmentin tablets instead have dose-adjustment instructions for severe renal impairment, although the 875 mg/125 mg conventional strength should not be used when GFR is below 30 mL/min. These differences require professional assessment and do not authorize patients to modify a prescribed regimen or substitute another formulation independently.

If the prescription is for XR, the pharmacy should verify whether the actual product is stocked or orderable and whether the available item is the brand, an authorized generic or a separately approved extended-release generic. A database entry alone is not proof of a fillable prescription.

A patient should not use leftover conventional tablets, plain amoxicillin or a different Augmentin formulation in place of XR. Antibiotic treatment must be based on appropriate clinical assessment and a valid prescription.

The penicillin allergy guide covers hypersensitivity context, while Augmentin delivery addresses product-specific fulfillment and shipment conditions.